Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME ®. This is a long-term clinical trial investigating cardiovascular (CV) ...
NEW ORLEANS — The potential mechanisms by which the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance, Lilly/Boehringer Ingelheim) may have reduced cardiovascular death in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results